Nesvacumab
Monoclonal antibody
- none
- Investigational
- 1296818-77-3
- 8457
- none
- WX8293WGLC
- D10395
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.[1][2] As of May 2017[update], it is in Phase II clinical trials for the treatment of diabetic macular edema.[3][4]
This drug is being developed by Regeneron Pharmaceuticals.[citation needed]
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
- ^ Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA (October 2019). "Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease". Expert Opinion on Investigational Drugs. 28 (10): 861–869. doi:10.1080/13543784.2019.1667333. PMID 31513439.
- ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
- ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e